News Image

Immatics Announces Full Year 2024 Financial Results and Business Update

Provided By GlobeNewswire

Last update: Mar 27, 2025

Houston, Texas and Tuebingen, Germany, March 27, 2025 Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024.

Read more at globenewswire.com

IMMATICS NV

NASDAQ:IMTX (7/25/2025, 8:00:01 PM)

After market: 6.56 0 (0%)

6.56

+0.11 (+1.71%)



Find more stocks in the Stock Screener

Follow ChartMill for more